Zhejiang Garden Biopharmaceutical Co.,Ltd. (300401.SZ)
- Previous Close
15.84 - Open
15.76 - Bid 16.12 x --
- Ask 16.13 x --
- Day's Range
15.63 - 16.30 - 52 Week Range
10.88 - 18.46 - Volume
23,802,951 - Avg. Volume
21,764,016 - Market Cap (intraday)
8.761B - Beta (5Y Monthly) 0.45
- PE Ratio (TTM)
29.31 - EPS (TTM)
0.55 - Earnings Date --
- Forward Dividend & Yield 0.07 (0.51%)
- Ex-Dividend Date May 15, 2024
- 1y Target Est
15.00
Zhejiang Garden Biopharmaceutical Co.,Ltd. manufactures and supplies lanolin cholesterol, vitamin D3, 25-hydroxyvitamin D3, and refined lanolin products in China. It offers cholesterol; feed grade cholesterol; food additives compound nutrient fortifier SDS, CO, and MO; cholecalciferol; feed additive - vitamin D3 particles and oil; VD3 resin oil; 25 hydroxyvitamin D3 progen and powder; 25 hydroxyvitamin D3; anhydrous lanolin; wood oil; wool wax; low chroma pure fat; lanolin alcohol; isopropyl lanolate; lanolinic acid; high acid fat; wood acid biofuel/wood alcohol biofuel; and rodenticide made from Vitamin D3. The company was formerly known as Zhejiang Garden Bio-chemical High-tech Co., Ltd. and changed its name to Zhejiang Garden Biopharmaceutical Co.,Ltd. in April 2023. Zhejiang Garden Biopharmaceutical Co.,Ltd. was founded in 2000 and is based in Dongyang, China.
www.hybiotech.com--
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: 300401.SZ
View MorePerformance Overview: 300401.SZ
Trailing total returns as of 5/16/2025, which may include dividends or other distributions. Benchmark is SSE Composite Index (000001.SS) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 300401.SZ
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 300401.SZ
View MoreValuation Measures
Market Cap
8.76B
Enterprise Value
9.15B
Trailing P/E
29.31
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
7.49
Price/Book (mrq)
2.62
Enterprise Value/Revenue
7.38
Enterprise Value/EBITDA
22.93
Financial Highlights
Profitability and Income Statement
Profit Margin
24.87%
Return on Assets (ttm)
3.63%
Return on Equity (ttm)
10.12%
Revenue (ttm)
1.24B
Net Income Avi to Common (ttm)
309.21M
Diluted EPS (ttm)
0.55
Balance Sheet and Cash Flow
Total Cash (mrq)
1.42B
Total Debt/Equity (mrq)
53.30%
Levered Free Cash Flow (ttm)
-201.29M